
Cancer Immunotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments
- AMR-1066906
- May 2021
- Biotechnology
- 117 Pages
Report Parameters | Details of Parameter |
Market Size | xx Million |
Based Year | 2020 |
Forecast Period Covered | 2020 – 2028 |
Units for value | Revenue in USD million and CAGR from 2020 to 2028 |
Covered Segments | Component, Types, Applications, End-Users, and more. |
Companies Covered | F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., Astrazeneca plc. |
Region Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.
Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Cancer Immunotherapy market along with their effects over the forecast period. Similarly, according to the region Cancer Immunotherapy market research report includes the study of opportunities available in the market situation.
The Cancer Immunotherapy market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
Major Key Players for Global Cancer Immunotherapy Market:
The Cancer Immunotherapy market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., Astrazeneca plc.
Cancer Immunotherapy Market Segmentation Analysis:
By Therapy
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Head and neck cancer
Ovarian cancer
Others
End User
Hospitals
Ambulatory Surgery Centers
Cancer Research Centers
Specialty Clinics
Global Cancer Immunotherapy Market Segmentation by Regions:
In regional analysis, Cancer Immunotherapy market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Cancer Immunotherapy market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.
North America Region for Cancer Immunotherapy Market: Value and Forecast
- U.S.
- Canada
- UK
- Germany
- France
- Rest of the Europe
- China
- Japan
- India
- Rest of the Asia Pacific
- Mexico
- Brazil
- Rest of the Latin America
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Important Points Covered by Report:
- To analyze the value of the Cancer Immunotherapy market, according to the key region.
- To study the Cancer Immunotherapy market current trends, prospects and also their participation in the entire sector.
- Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
- Report provides the detailed information about drivers, restraints and future scope of Cancer Immunotherapy market.
- Report covers the information about historic data analysis as well as forecast period analysis.
Global Cancer Immunotherapy research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Cancer Immunotherapy market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Cancer Immunotherapy market for numerous purposes such as:
1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.
2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Cancer Immunotherapy market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Cancer Immunotherapy market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.
3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Cancer Immunotherapy market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.
Manufacturers and Segments
- F. Hoffmann-La Roche AG
- Advaxis Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Novartis AG
- Bayer AG
- Immunomedics Inc.
- Astrazeneca plc.
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Hospitals
- Ambulatory Surgery Centers
- Cancer Research Centers
- Specialty Clinics
Have query on this report?
Make an Enquiry
1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
2. Executive Summarysegment Form
2.1. Global Cancer Immunotherapy Market Snapshot
2.1.1. Global Cancer Immunotherapy Market By Therapy,2019
2.1.1.1.Monoclonal Antibodies
2.1.1.2.Immune Checkpoint Inhibitors
2.1.1.3.Immune System Modulators
2.1.1.4.Cancer Vaccines
2.1.2. Global Cancer Immunotherapy Market By End User,2019
2.1.2.1.Hospitals
2.1.2.2.Ambulatory Surgery Centers
2.1.2.3.Cancer Research Centers
2.1.2.4.Specialty Clinics
2.1.3. Global Cancer Immunotherapy Market By End-use,2019
2.1.4. Global Cancer Immunotherapy Market By Geography,2019
3. Global Cancer Immunotherapy Market Dynamics
3.1. Market Overview
3.2. Market Inclination Insights Analysis
3.3. Drivers
3.4. Challenges
3.5. Future Prospects
3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)
4. Global Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
4.1. Overview
4.1.1. Market Share Analysis By Therapy, 2019 vs.2028
4.1.2. Attractive Investment Proposition By Therapy, 2020
4.2. Global Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
5. Global Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
5.1. Overview
5.1.1. Market Share Analysis By End User, 2019 vs.2028
5.1.2. Attractive Investment Proposition By End User, 2020
5.2. Global Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
6. Global Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
6.1. Overview
6.1.1. Market Share Analysis By End-use, 2019 vs.2028
6.1.2. Attractive Investment Proposition By End-use, 2020
6.2. Global Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7. Global Cancer Immunotherapy Market Size (US$), By Geography, 2018 – 2028
7.1. Overview
7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
7.1.2. Attractive Investment Proposition by Geography, 2020
7.2. North America Cancer Immunotherapy Market Analysis, 2018 – 2028
7.2.1. North America Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. North America Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.2.3. North America Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.2.4. North America Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.3. Europe Cancer Immunotherapy Market Analysis, 2018 – 2028
7.3.1. Europe Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.3.1.1. U.K.
7.3.1.2. Germany
7.3.1.3. France
7.3.1.4. Rest of Europe
7.3.2. Europe Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.3.3. Europe Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.3.4. Europe Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.4. Asia Pacific Cancer Immunotherapy Market Analysis , 2018 – 2028
7.4.1. Asia Pacific Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. Rest of Asia Pacific
7.4.2. Asia Pacific Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.4.3. Asia Pacific Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.4.4. Asia Pacific Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.5. Latin America Cancer Immunotherapy Market Analysis, 2018 – 2028
7.5.1. Latin America Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.5.3. Latin America Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.5.4. Latin America Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.6. Middle East & Africa (MEA) Cancer Immunotherapy Market Analysis, 2018 – 2028
7.6.1. MEA Cancer Immunotherapy Market Size (US$), By Region, 2018 – 2028
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of MEA
7.6.2. MEA Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.6.3. MEA Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.6.4. MEA Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
8. Company Profiles
8.1. Competitive Analysis
8.2. Market Positioning of Key Vendors
8.3. Key Strategies adopted by the Leading Players
8.4. Key Cancer Immunotherapy Providers
8.4.1 F. Hoffmann-La Roche AG
8.4.1.1 Business Description
8.4.1.2 F. Hoffmann-La Roche AG Geographic Operations
8.4.1.3 F. Hoffmann-La Roche AG Financial Information
8.4.1.4 F. Hoffmann-La Roche AG Product Positions/Portfolio
8.4.1.5 F. Hoffmann-La Roche AG Key Developments
8.4.2 Advaxis Inc.
8.4.2.1 Business Description
8.4.2.2 Advaxis Inc. Geographic Operations
8.4.2.3 Advaxis Inc. Financial Information
8.4.2.4 Advaxis Inc. Product Positions/Portfolio
8.4.2.5 Advaxis Inc. Key Developments
8.4.3 Merck & Co., Inc.
8.4.3.1 Business Description
8.4.3.2 Merck & Co., Inc. Geographic Operations
8.4.3.3 Merck & Co., Inc. Financial Information
8.4.3.4 Merck & Co., Inc. Product Positions/Portfolio
8.4.3.5 Merck & Co., Inc. Key Developments
8.4.4 Eli Lilly and Company
8.4.4.1 Business Description
8.4.4.2 Eli Lilly and Company Geographic Operations
8.4.4.3 Eli Lilly and Company Financial Information
8.4.4.4 Eli Lilly and Company Product Positions/Portfolio
8.4.4.5 Eli Lilly and Company Key Developments
8.4.5 Bristol-Myers Squibb Company
8.4.5.1 Business Description
8.4.5.2 Bristol-Myers Squibb Company Geographic Operations
8.4.5.3 Bristol-Myers Squibb Company Financial Information
8.4.5.4 Bristol-Myers Squibb Company Product Positions/Portfolio
8.4.5.5 Bristol-Myers Squibb Company Key Developments
8.4.6 Pfizer Inc.
8.4.6.1 Business Description
8.4.6.2 Pfizer Inc. Geographic Operations
8.4.6.3 Pfizer Inc. Financial Information
8.4.6.4 Pfizer Inc. Product Positions/Portfolio
8.4.6.5 Pfizer Inc. Key Developments
8.4.7 Novartis AG
8.4.7.1 Business Description
8.4.7.2 Novartis AG Geographic Operations
8.4.7.3 Novartis AG Financial Information
8.4.7.4 Novartis AG Product Positions/Portfolio
8.4.7.5 Novartis AG Key Developments
8.4.8 Bayer AG
8.4.8.1 Business Description
8.4.8.2 Bayer AG Geographic Operations
8.4.8.3 Bayer AG Financial Information
8.4.8.4 Bayer AG Product Positions/Portfolio
8.4.8.5 Bayer AG Key Developments
8.4.9 Immunomedics Inc.
8.4.9.1 Business Description
8.4.9.2 Immunomedics Inc. Geographic Operations
8.4.9.3 Immunomedics Inc. Financial Information
8.4.9.4 Immunomedics Inc. Product Positions/Portfolio
8.4.9.5 Immunomedics Inc. Key Developments
8.4.10 Astrazeneca plc.
8.4.10.1 Business Description
8.4.10.2 Astrazeneca plc. Geographic Operations
8.4.10.3 Astrazeneca plc. Financial Information
8.4.10.4 Astrazeneca plc. Product Positions/Portfolio
8.4.10.5 Astrazeneca plc. Key Developments
LIST OF TABLES
TABLE 1 Market Snapshot: Global Cancer Immunotherapy Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 North America Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 5 North America Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 6 North America Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 7 Europe Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 8 Europe Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 9 Europe Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 10 Asia Pacific Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 11 Asia Pacific Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 12 Asia Pacific Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 13 Latin America Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 14 Latin America Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 15 Latin America Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 17 MEA Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 18 MEA Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
LIST OF FIGURES
FIG. 1 Global Cancer Immunotherapy: Market Segmentation
FIG. 2 Global Cancer Immunotherapy Market: Research Methodology
FIG. 3 Top-Down and Bottom-up Approach
FIG. 4 Global Cancer Immunotherapy Market, By Therapy, 2019 (US$ Mn)
FIG. 5 Global Cancer Immunotherapy Market, By End User, 2019 (US$ Mn)
FIG. 6 Global Cancer Immunotherapy Market, By End-use, 2019 (US$ Mn)
FIG. 7 Global Cancer Immunotherapy Market, By Geography, 2019 (US$ Mn)
FIG. 8 Global Cancer Immunotherapy Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition
FIG. 10 Market Positioning of Key Cancer Immunotherapy Providers, 2019
FIG. 11 Global Cancer Immunotherapy Market Revenue Contribution, By Therapy, 2019 & 2028 (Value %)
FIG. 12 Global Cancer Immunotherapy Market Revenue Contribution, By End User, 2019 & 2028 (Value %)
FIG. 13 Global Cancer Immunotherapy Market Revenue Contribution, By End-use, 2019 & 2028 (Value %)
FIG. 14 North America Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 15 Europe Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 16 Asia Pacific Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 17 Latin America Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
Key Takeaways:
1. Market value and estimate of the Cancer Immunotherapy market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
2. Executive Summarysegment Form
2.1. Global Cancer Immunotherapy Market Snapshot
2.1.1. Global Cancer Immunotherapy Market By Therapy,2019
2.1.1.1.Monoclonal Antibodies
2.1.1.2.Immune Checkpoint Inhibitors
2.1.1.3.Immune System Modulators
2.1.1.4.Cancer Vaccines
2.1.2. Global Cancer Immunotherapy Market By End User,2019
2.1.2.1.Hospitals
2.1.2.2.Ambulatory Surgery Centers
2.1.2.3.Cancer Research Centers
2.1.2.4.Specialty Clinics
2.1.3. Global Cancer Immunotherapy Market By End-use,2019
2.1.4. Global Cancer Immunotherapy Market By Geography,2019
3. Global Cancer Immunotherapy Market Dynamics
3.1. Market Overview
3.2. Market Inclination Insights Analysis
3.3. Drivers
3.4. Challenges
3.5. Future Prospects
3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)
4. Global Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
4.1. Overview
4.1.1. Market Share Analysis By Therapy, 2019 vs.2028
4.1.2. Attractive Investment Proposition By Therapy, 2020
4.2. Global Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
5. Global Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
5.1. Overview
5.1.1. Market Share Analysis By End User, 2019 vs.2028
5.1.2. Attractive Investment Proposition By End User, 2020
5.2. Global Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
6. Global Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
6.1. Overview
6.1.1. Market Share Analysis By End-use, 2019 vs.2028
6.1.2. Attractive Investment Proposition By End-use, 2020
6.2. Global Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7. Global Cancer Immunotherapy Market Size (US$), By Geography, 2018 – 2028
7.1. Overview
7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
7.1.2. Attractive Investment Proposition by Geography, 2020
7.2. North America Cancer Immunotherapy Market Analysis, 2018 – 2028
7.2.1. North America Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. North America Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.2.3. North America Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.2.4. North America Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.3. Europe Cancer Immunotherapy Market Analysis, 2018 – 2028
7.3.1. Europe Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.3.1.1. U.K.
7.3.1.2. Germany
7.3.1.3. France
7.3.1.4. Rest of Europe
7.3.2. Europe Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.3.3. Europe Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.3.4. Europe Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.4. Asia Pacific Cancer Immunotherapy Market Analysis , 2018 – 2028
7.4.1. Asia Pacific Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. Rest of Asia Pacific
7.4.2. Asia Pacific Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.4.3. Asia Pacific Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.4.4. Asia Pacific Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.5. Latin America Cancer Immunotherapy Market Analysis, 2018 – 2028
7.5.1. Latin America Cancer Immunotherapy Market Size (US$), By Country, 2018 – 2028
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.5.3. Latin America Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.5.4. Latin America Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
7.6. Middle East & Africa (MEA) Cancer Immunotherapy Market Analysis, 2018 – 2028
7.6.1. MEA Cancer Immunotherapy Market Size (US$), By Region, 2018 – 2028
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of MEA
7.6.2. MEA Cancer Immunotherapy Market Size (US$), By Therapy, 2018 – 2028
7.6.3. MEA Cancer Immunotherapy Market Size (US$), By End User, 2018 – 2028
7.6.4. MEA Cancer Immunotherapy Market Size (US$), By End-use, 2018 – 2028
8. Company Profiles
8.1. Competitive Analysis
8.2. Market Positioning of Key Vendors
8.3. Key Strategies adopted by the Leading Players
8.4. Key Cancer Immunotherapy Providers
8.4.1 F. Hoffmann-La Roche AG
8.4.1.1 Business Description
8.4.1.2 F. Hoffmann-La Roche AG Geographic Operations
8.4.1.3 F. Hoffmann-La Roche AG Financial Information
8.4.1.4 F. Hoffmann-La Roche AG Product Positions/Portfolio
8.4.1.5 F. Hoffmann-La Roche AG Key Developments
8.4.2 Advaxis Inc.
8.4.2.1 Business Description
8.4.2.2 Advaxis Inc. Geographic Operations
8.4.2.3 Advaxis Inc. Financial Information
8.4.2.4 Advaxis Inc. Product Positions/Portfolio
8.4.2.5 Advaxis Inc. Key Developments
8.4.3 Merck & Co., Inc.
8.4.3.1 Business Description
8.4.3.2 Merck & Co., Inc. Geographic Operations
8.4.3.3 Merck & Co., Inc. Financial Information
8.4.3.4 Merck & Co., Inc. Product Positions/Portfolio
8.4.3.5 Merck & Co., Inc. Key Developments
8.4.4 Eli Lilly and Company
8.4.4.1 Business Description
8.4.4.2 Eli Lilly and Company Geographic Operations
8.4.4.3 Eli Lilly and Company Financial Information
8.4.4.4 Eli Lilly and Company Product Positions/Portfolio
8.4.4.5 Eli Lilly and Company Key Developments
8.4.5 Bristol-Myers Squibb Company
8.4.5.1 Business Description
8.4.5.2 Bristol-Myers Squibb Company Geographic Operations
8.4.5.3 Bristol-Myers Squibb Company Financial Information
8.4.5.4 Bristol-Myers Squibb Company Product Positions/Portfolio
8.4.5.5 Bristol-Myers Squibb Company Key Developments
8.4.6 Pfizer Inc.
8.4.6.1 Business Description
8.4.6.2 Pfizer Inc. Geographic Operations
8.4.6.3 Pfizer Inc. Financial Information
8.4.6.4 Pfizer Inc. Product Positions/Portfolio
8.4.6.5 Pfizer Inc. Key Developments
8.4.7 Novartis AG
8.4.7.1 Business Description
8.4.7.2 Novartis AG Geographic Operations
8.4.7.3 Novartis AG Financial Information
8.4.7.4 Novartis AG Product Positions/Portfolio
8.4.7.5 Novartis AG Key Developments
8.4.8 Bayer AG
8.4.8.1 Business Description
8.4.8.2 Bayer AG Geographic Operations
8.4.8.3 Bayer AG Financial Information
8.4.8.4 Bayer AG Product Positions/Portfolio
8.4.8.5 Bayer AG Key Developments
8.4.9 Immunomedics Inc.
8.4.9.1 Business Description
8.4.9.2 Immunomedics Inc. Geographic Operations
8.4.9.3 Immunomedics Inc. Financial Information
8.4.9.4 Immunomedics Inc. Product Positions/Portfolio
8.4.9.5 Immunomedics Inc. Key Developments
8.4.10 Astrazeneca plc.
8.4.10.1 Business Description
8.4.10.2 Astrazeneca plc. Geographic Operations
8.4.10.3 Astrazeneca plc. Financial Information
8.4.10.4 Astrazeneca plc. Product Positions/Portfolio
8.4.10.5 Astrazeneca plc. Key Developments
LIST OF TABLES
TABLE 1 Market Snapshot: Global Cancer Immunotherapy Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 North America Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 5 North America Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 6 North America Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 7 Europe Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 8 Europe Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 9 Europe Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 10 Asia Pacific Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 11 Asia Pacific Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 12 Asia Pacific Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 13 Latin America Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 14 Latin America Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 15 Latin America Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Cancer Immunotherapy Market Revenue, By Therapy, 2018 – 2028 (US$ Mn)
TABLE 17 MEA Cancer Immunotherapy Market Revenue, By End User, 2018 – 2028 (US$ Mn)
TABLE 18 MEA Cancer Immunotherapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
LIST OF FIGURES
FIG. 1 Global Cancer Immunotherapy: Market Segmentation
FIG. 2 Global Cancer Immunotherapy Market: Research Methodology
FIG. 3 Top-Down and Bottom-up Approach
FIG. 4 Global Cancer Immunotherapy Market, By Therapy, 2019 (US$ Mn)
FIG. 5 Global Cancer Immunotherapy Market, By End User, 2019 (US$ Mn)
FIG. 6 Global Cancer Immunotherapy Market, By End-use, 2019 (US$ Mn)
FIG. 7 Global Cancer Immunotherapy Market, By Geography, 2019 (US$ Mn)
FIG. 8 Global Cancer Immunotherapy Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition
FIG. 10 Market Positioning of Key Cancer Immunotherapy Providers, 2019
FIG. 11 Global Cancer Immunotherapy Market Revenue Contribution, By Therapy, 2019 & 2028 (Value %)
FIG. 12 Global Cancer Immunotherapy Market Revenue Contribution, By End User, 2019 & 2028 (Value %)
FIG. 13 Global Cancer Immunotherapy Market Revenue Contribution, By End-use, 2019 & 2028 (Value %)
FIG. 14 North America Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 15 Europe Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 16 Asia Pacific Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 17 Latin America Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Cancer Immunotherapy Market Revenue, 2018 – 2028, (US$ Mn)
Key Takeaways:
1. Market value and estimate of the Cancer Immunotherapy market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage
List of Tables
TABLE Market Snapshot: Global Cancer Immunotherapy MarketTABLE Impact Pointers
TABLE Impact Analysis of Drivers and Restraints
TABLE North America Cancer Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE North America Cancer Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE North America Cancer Immunotherapy Market Value, By Country, 2018 – 2028
TABLE Europe Cancer Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE Europe Cancer Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE Europe Cancer Immunotherapy Market Value, By Country, 2018 – 2028
TABLE Asia Pacific Cancer Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE Asia Pacific Cancer Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE Asia Pacific Cancer Immunotherapy Market Value, By Country, 2018 – 2028
TABLE Latin America Cancer Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE Latin America Cancer Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE Latin America Cancer Immunotherapy Market Value, By Country, 2018 – 2028
TABLE MEA Cancer Immunotherapy Market Value, By Segment1, 2018 – 2028
TABLE MEA Cancer Immunotherapy Market Value, By Segment2, 2018 – 2028
TABLE MEA Cancer Immunotherapy Market Value, By Country, 2018 – 2028
TABLE F. Hoffmann-La Roche AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Advaxis Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Merck & Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Bristol-Myers Squibb Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Immunomedics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE Astrazeneca plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
List of Figures
FIG. Global Cancer Immunotherapy Market: Research MethodologyFIG. Top-Down and Bottom Up Approach
FIG. Global Cancer Immunotherapy Market, By Segment1, 2019 (US$ Mn)
FIG. Global Cancer Immunotherapy Market, By Segment2, 2019 (US$ Mn)
FIG. Global Cancer Immunotherapy Market, By Geography, 2019 (US$ Mn)
FIG. Global Cancer Immunotherapy Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. Attractive Investment Proposition
FIG. Market Positioning of Key Cancer Immunotherapy Providers, 2016
FIG. Global Cancer Immunotherapy Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG. Global Immune Checkpoint Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Immune System Modulators Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Cancer Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Cancer Immunotherapy Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG. Global Ambulatory Surgery Centers Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Cancer Research Centers Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Specialty Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG. Global Market Value, 2018 – 2028, (US$ Mn)
FIG. U.S. Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Canada Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. UK Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Germany Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. France Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Europe Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. China Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Japan Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. India Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Asia Pacific Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Mexico Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Brazil Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of Latin America Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. GCC Countries Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. South Africa Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG. Rest of MEA Cancer Immunotherapy Market Value, 2018 – 2028, (US$ Mn)